Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Change in Intangibles (2022 - 2025)

Gyre Therapeutics (GYRE) has disclosed Change in Intangibles for 3 consecutive years, with $15000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Intangibles changed N/A to $15000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $738000.0, a N/A change, with the full-year FY2023 number at $69000.0, up 430.77% from a year prior.
  • Change in Intangibles was $15000.0 for Q3 2025 at Gyre Therapeutics, down from $23000.0 in the prior quarter.
  • In the past five years, Change in Intangibles ranged from a high of $699000.0 in Q1 2025 to a low of -$55.0 million in Q4 2022.
  • A 3-year average of -$6.8 million and a median of $8500.0 in 2023 define the central range for Change in Intangibles.
  • Biggest YoY gain for Change in Intangibles was 100.0% in 2023; the steepest drop was 100.0% in 2023.
  • Gyre Therapeutics' Change in Intangibles stood at -$55.0 million in 2022, then skyrocketed by 100.0% to $1000.0 in 2023, then surged by 1400.0% to $15000.0 in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Change in Intangibles are $15000.0 (Q3 2025), $23000.0 (Q2 2025), and $699000.0 (Q1 2025).